Compare Guardant Health Inc. Common Stock (GH) vs Blue Owl Capital Inc. Class A Common Stock (OWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Guardant Health Inc. Common Stock vs Blue Owl Capital Inc. Class A Common Stock — how do they compare? Guardant Health Inc. Common Stock trades at $162.64 (market cap $21.74B), while Blue Owl Capital Inc. Class A Common Stock trades at $8.78 (market cap $6.35B). The key difference: Guardant Health Inc. Common Stock is far larger — about 3.4× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays a 9.8% dividend while Guardant Health Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 3 Days and Blue Owl Capital Inc. Class A Common Stock for 0 Days on average.
| GH | OWL | |
|---|---|---|
Market Cap | $21.74B | $6.35B |
Volume | 1,297,295 | 15,716,423 |
Sector | Health | Financials |
52-Week High | $187.22 | $17.17 |
52-Week Low | $64.19 | $8.23 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $22.38B | $10.53B |
Dividend Yield | — | 9.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Guardant Health (GH) trades at $162.09, down 0.43% today, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth to $982M in 2025 but remains unprofitable with a -38.33% net margin. Recent FDA and European approvals for cancer diagnostics and expanded insurance coverage provide significant growth catalysts.
Investment outlook balances high growth potential against persistent losses. Analyst consensus is strongly bullish with a $202.40 price target (25% upside), but investors face execution risk as the company burns cash and misses earnings estimates. The stock offers substantial upside if Guardant can achieve profitability through its expanding product portfolio.
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Guardant Health Inc. Common Stock
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →
